/PRNewswire/ Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic.
Cancer patients and the COVID-19 vaccines
Clinicians, cancer patients and coronavirus researchers weigh in on vaccination safety, timing, allergy concerns and more January 14, 2021 • By Diane Mapes / Fred Hutch News Service Metastatic breast cancer patient and family doctor Dr. Carla Kakuta of Winters, California, receives her first COVID-19 shot, before heading off to cancer treatment. I went straight from vaccination to the infusion center because I’m awesome like that, she wrote on Twitter. “I ve been seeing patients in person through the pandemic. Since Thanksgiving the % positive rate of the people I test has been 15 to 20%. Grateful I’ve been able to avoid bringing it home to my family.
The American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH) have developed joint clinical practice guidelines on the diagnosis and management of von Willebrand Disease (VWD), the world's most common inherited bleeding disorder. The guidelines were published today in Blood Advances.
Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones
Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today provided a review of corporate highlights from 2020 and outlined anticipated key clinical program milestones for 2021. While 2020 was marked by tremendous challenges due to the COVID-19 pandemic, Forma made important strides due to the courage of patients and the dedication of our employees. We reported promising results our from our clinical programs including FT-4202 in sickle cell disease, olutasidenib in both AML and glioma, and FT-7051 in prostate cancer, and also raised approximately $695 million in public equity offerings, said Frank Lee, president and chief executive officer of Forma. In this coming year, we anticipate continued progress, and look forward to advancing drug
/PRNewswire/ - The American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF),.